Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: The Company manufactures and sells apparatus, instruments, devices, and consumables for life science research. Operations are focused on the Apparatus and Instrumentation business segment following the divestiture of the Capital Equipment Business segment in 2008. The Company operates globally with significant exposure to foreign currencies, particularly the British Pound and Euro.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Revenues | $18,049 | $37,121 |
| Gross Profit | $8,942 | $18,352 |
| Gross Margin % | 49.5% | 49.4% |
| Operating Income | $805 | $3,156 |
| Net Income (Continuing Ops) | $281 | $2,120 |
| Diluted EPS (Continuing Ops) | $0.01 | $0.07 |
| Cash and Cash Equivalents | $16,801 (Balance Sheet) | N/A |
| Net Cash from Operating Activities | N/A | $6,721 |
| Long-Term Debt | $0 | $0 |
| Current Debt (Notes Payable) | $533 | $533 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 21.7% ($5.0 million) for the three months and 17.5% ($7.9 million) for the six months ended June 30, 2009, compared to the prior year periods.
- Foreign Exchange Impact: A strengthened U.S. dollar reduced revenues by approximately 6.9% ($1.6 million) in Q2 and 10.0% ($4.5 million) for the six-month period.
- Organic Trends: Adjusting for currency, revenues were down due to a weaker economic environment and an exceptionally strong comparison quarter in 2008.
- Margin Expansion: Gross margin percentage improved to 49.5% (Q2) and 49.4% (YTD) from 46.7% and 46.9% in the prior year, driven by production efficiency improvements and a favorable sales mix.
- Restructuring Charges: The Company recorded $0.4 million in restructuring charges for Q2 2009 and $0.5 million for the six months, related to the 2009 plan to relocate Scie-Plas operations and exit general fabrication. This compares to $0.9 million and $1.5 million in the prior year periods.
- Discontinued Operations: The prior year periods included significant losses from discontinued operations ($3.3 million loss in Q2 2008; $3.8 million loss YTD 2008) related to the divestiture of the Capital Equipment Business. No such losses were recorded in 2009.
Guidance, Outlook, and Risks
- Management Commentary: Management views Q2 2009 as a transition quarter. While revenue missed expectations, order intake improved significantly in June, suggesting the worst of the recession may be behind the Company. Bookings increased 6% sequentially in Q2.
- Strategic Initiatives: The Company continues to invest in growth initiatives despite the recession, including the launch of Biochrom US, new product introductions (e.g., PHD Ultra syringe pumps), and catalog mailings. Operational improvements, including restructuring at Biochrom and relocating Scie-Plas, are ongoing.
- Liquidity and Capital Resources:
- Cash and cash equivalents increased to $16.8 million as of June 30, 2009.
- The Company has a $20.0 million revolving credit facility with no borrowings outstanding as of June 30, 2009.
- Subsequent Event: On August 7, 2009, the Company entered into an amended and restated $20.0 million credit facility maturing in August 2012, bearing interest at LIBOR plus 4.0%.
- Risks and Contingencies:
- Foreign Currency: Approximately 58% of revenues are derived from business in British Pounds or Euros. Continued strengthening of the U.S. dollar poses a significant headwind to earnings and cash flows.
- Economic Conditions: Demand is sensitive to the financial position of university and pharmaceutical customers and general economic trends.
- Acquisition Strategy: Future growth relies on acquisitions, which may require raising additional capital through debt or equity.
Key Facts for Investor Verification
- Currency Sensitivity: Verify the extent of the U.S. dollar's impact on future quarters, as 58% of revenue is foreign-denominated and the dollar has appreciated significantly against the Pound and Euro.
- Order Intake vs. Revenue: Confirm if the reported improvement in order intake (bookings up 6% sequentially) translates into revenue growth in Q3 and Q4 2009.
- Restructuring Progress: Monitor the completion of the Scie-Plas relocation and Biochrom restructuring to ensure anticipated cost savings are realized.
- Stock Repurchases: The Company repurchased 811,872 shares for $2.4 million in the first half of 2009, with $5.0 million remaining under the authorization.
- Discontinued Operations: Ensure future comparisons exclude the significant losses from the Capital Equipment Business divestiture recorded in 2008.